CClinicalTrials.gg
Sign In
CompletedNCT03403114SPECIVACUpdated Apr 19, 2021

Vaccine Attitudes and Practices of Hospital Specialists

An observational study in Vaccine Practice, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 14 sites in France. Per ClinicalTrials.gov, last updated 2021-04-19.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
1,851
Sex
All
01

Study summary

This study aims to evaluate the perceptions and knowledge of hospital specialists regarding vaccine recommendations targeting their patients, to study their behavior with respect to these recommendations and to quantify their vaccine hesitancy.

02

Conditions studied

  • Vaccine Practice

Keywords

  • Vaccine hesitancy
  • Hospital specialists (HS)
  • Vaccination survey
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  • Physicians with a frequent activity of practice and advice vaccines, called "vaccinators" (most medical specialties): 100% of those meeting the inclusion criteria will be contacted for inclusion
  • Physicians "no or weak vaccinators" (anesthesiologists, surgeons, psychiatrists...): 30% of those meeting the inclusion criteria will be chosen by drawing lots

Inclusion criteria

  • To be a physician in one of the participating institutions
  • Or to be a contract physician in participating institutions

Exclusion criteria

Exclusion Criteria:

  • Interns
  • Attached practitioners
  • Emergency physicians
04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
1,851 participants (actual)
Patient registry
No

Interventions

  • BehavioralQuestionnaire

    a 15min questionnaire

05

What researchers measure

Primary outcomes

  1. Proportions of Hospital Specialists (HS) with knowledge of vaccine recommendations targeting their patients

    Time frame: 15 minutes

  2. Proportions of HS regularly recommending recommended vaccines to their patients

    Time frame: 15 minutes

  3. Proportions of HS with doubts about recommended vaccines

    Time frame: 15 minutes

Secondary outcomes

  1. Link between perception of benefits and risks of vaccines, knowledge of vaccine-preventable diseases, trust in different sources of information and vaccine hesitancy will be measured by questionnaire (measure by multiple logistic regressions)

    Time frame: 15 minutes

  2. Measure of attitudes and practices of HS vis-a-vis to vaccination and their specialty by questionnaire

    number of HS vaccinator or not by specialty in connection with their attitudes and practices

    Time frame: 15 minutes

  3. Percentages of HS feeling sufficiently trained or confident to explain to patients about vaccines

    Time frame: 15 minutes

  4. Percentages of HS claiming to be vaccinated, by type of vaccine

    Time frame: 15 minutes

  5. Percentages of HS children reported vaccinated by type of vaccine

    Time frame: 15 minutes

06

Study locations

14 sites
  • CIC Cochin Pasteur
    Paris, Ile De France 75014, France
  • CIC Bichat
    Paris, Ile De France 75877, France
  • CRC Annecy
    Annecy, 74370, France
  • CIC Besançon
    Besançon, 25030, France
  • CIC Clermont-Ferrand
    Clermont-Ferrand, 63003, France
  • CIC Dijon
    Dijon, 21079, France
  • CIC Lille
    Lille, 59045, France
  • CIC Limoges
    Limoges, 87042, France
  • Service d'Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Edouard Herriot et Unité de recherche clinique ne Immunologie du centre hospitalier Lyon Sud
    Lyon, 69437, France
  • CIC Montpellier
    Montpellier, 34295, France
  • Service de maladies infectieuses Nancy
    Nancy, 54511, France
  • Service de maladies infectieuses Nîmes
    Nîmes, 30029, France
  • CIC Rennes
    Rennes, 35033, France
  • CIC Strasbourg
    Strasbourg, 67000, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03403114
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Innovative clinical research network in vaccinology (I-REIVAC), Observatoire Régionale de la santé ORS-PACA
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
Feb 1, 2018
Primary completion
Oct 4, 2019
Completion
Oct 4, 2019
Last update
Apr 19, 2021

Study contacts

Odile LAUNAY, Professor
principal investigator · CIC 1417 Centre d'investigation clinique
Pierre VERGER, MD
study chair · ORS PACA UMR 912 SESSTIM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Assistance Publique - Hôpitaux de Paris

Start the discussion